Company intelligence / Profile preview
Wuhan Si'an Medical Technology
Wuhan, Hubei, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Wuhan Si'an Medical Technology is developing a range of autologous and other CAR-T cell therapies, with its lead anti-CD19 CAR-T candidate in Phase 3 for lymphoid malignancies and several ongoing early-stage clinical studies targeting B-cell maturation antigen for multiple myeloma, among others. Detailed public clinical efficacy data are not disclosed, but the company has ongoing clinical trials with at least one program reaching Phase 3[5][7].
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyTCR-T cell therapyCAR-NK cell therapyAutologous CAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Wuhan Si'an Medical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wuhan Si'an Medical Technology.